瑞舒伐他汀钙对急性期脑梗死患者血脂和C反应蛋白水平的影响被引量：12

Effect of Rosuvastatin on blood lipids and C-reactive protein in patients with acute cerebral infarction

下载PDF

导出

摘要目的观察瑞舒伐他汀钙对脑梗死患者的血脂和C反应蛋白(CRP)水平的影响。方法选取96例脑梗死合并高脂血症的患者,随机分为治疗组和对照组。治疗组应用瑞舒伐他汀钙治疗(10mg/d),对照组使用阿托伐他汀钙或其他他汀类药物治疗,用药2周后检测患者血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和CRP水平。结果与治疗前相比,2组患者血清TC、TG、LDL-C和CRP均有明显下降;与对照组比较,治疗组患者上述指标下降程度更大。结论瑞舒伐他汀钙能更有效降低脑梗死急性期患者的血脂及CRP水平。 Objective To observe the effects of Rosuvastatin on the level of blood lipids and C-reactive protein （CRP） in patients with cerebral infarction. Methods Ninety-six cases of patients with cerebral infarction and hyperlipidemia were selected and divided randomly into treatment and control group. Treatment group were administrated with Rosuvastatin calcium therapy （10mg/d）, and the control group received Atorvastatin or Simvasatin. Serum total cholesterol （TC）, triglyceride （TG）, low density lipoprotein cholesterol （LDL-C）, high density lipoorotein cholesterol （HDL-C） and CRP levels were detected after 2weeks. Results The levels of LDL-C and C-reactive protein in the treatment group were lower than that of the control group.Conclusion Rosuvastatin has a good effect on reducing the level of blood lipids and C-reactive protein in patients with acute cerebral infarction.

作者曾志磊杨霄鹏白宏英娄季宇

机构地区郑州大学第二附属医院神经内科

出处《中国实用神经疾病杂志》 2012年第10期21-23,共3页 Chinese Journal of Practical Nervous Diseases

关键词脑梗死 C反应蛋白瑞舒伐他汀钙血脂 Cerebral infarction C-reactive protein Rosuvastatin Atorvastatin

分类号 R743.33 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献6

1Jain KK. Neuroprotection in cerebrovascular disease[J]. Ex pert Opin Investig Drugs, 2000,9(4):695-711.
2Song IU, Kim JS, Kim YI, et al. Relationship between highsensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population[J]. Cerehrovasc Dis, 2009, 28(6):545-550.
3Jantzen F, K nemann S, Wolff B, et aI. Isoprenoid depletion by statins antagonizes cytokine induced down-regulation of en clothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells[J]. J Physiol Pharmacol, 2007, 58(3):503-514.
4Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients:the MERCURY U (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial [J]. J AmCollCardiol,2008, 52(8)=626-632.
5Chu AY, Guilianini F, Barratt BJ, et al. Pharmacogenetic de terminants of statin-induced reductions in C-reactive protein [J]. Circ Cardiovasc Genet, 2012, 5(1) :58-65.
6Sindhu S, Singh HK, Salman MT, et al. Effects of atorvasta- tin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients[J]. J Pharmacol Pharmacother, 2011, 2(4):261-265.